Nov 8, 2017
Lytix Biopharma will present two poster at SITC in Washington
Nov 1, 2017
Upcoming shareholder meetings in Harstad, Tromsø and Oslo
Oct 17, 2017
Changes to BoD in Lytix Biopharma as part of preparations for the IPO
Sep 20, 2017
Lytix among the speakers at Redeye’s ‘Fight cancer – immune-oncology’ conference
Sep 18, 2017
Lytix collaboration with Pittet mentioned in Nature Medicine
Sep 14, 2017
Lytix Biopharma among the speakers at Immuno-Oncology Frontiers in Berlin
Sep 7, 2017
Newsletter_September 2017
Sep 5, 2017
Edwin Klumper - new CEO in Lytix Biopharma
Sep 4, 2017
Lytix Biopharma will present two poster at CIMT Sept 8th
Aug 31, 2017
LTX-315’s ability to induce abscopal anticancer activity published in OncoImmunology
Aug 22, 2017
Norwegian Cancer Society invests in Lytix Biopharma AS
Aug 21, 2017
Lytix strengthens the board with clinical development and commercial oncology experience
Aug 15, 2017
Lytix Biopharma completes 1st cohort of LTX-315 monotherapy
Jul 3, 2017
2nd combination cohort of LTX-315 and pembrolizumab in TNBC completed
Jun 6, 2017
HalioDx SAS, an immuno-oncology diagnostic company, was co-authors at the poster of Phase I data on LTX-315 at ASCO
Jun 5, 2017
ASCO 2017 - Lytix Biopharma featured in Dagens Medisin
May 31, 2017
Lytix Biopharma will present poster at ASCO Monday June 5t 2017
May 24, 2017
Lytix Biopharma held company presentation at BioEquity Europe in Paris
May 23, 2017
Data on LTX-315 has been accepted for poster presentation at ASCO 2017
May 21, 2017
Immunotherapeutic effects of LTX-315 published in Future Medicinal Chemistry
Apr 21, 2017
Lytix Biopharma completes 1st combination cohort of LTX-315 and pembrolizumab in TNBC
Apr 21, 2017
Newsletter_April 2017
Apr 20, 2017
Lytix Biopharma raises in total 80 million NOK
Apr 6, 2017
Lytix Biopharma presented 4 posters at AACR in Washington April 2017
Apr 3, 2017
LTX-315 was presented at ICI Boston (a dedicated Cancer Immunotherapy meeting) in March 2017
Mar 23, 2017
Lytix Biopharma featured in Finansavisen, regarding pre-IPO and IPO
Mar 20, 2017
The repair share issue in Lytix Biopharma is now launched
Mar 20, 2017
Lytix Biopharma invites shareholders to information meetings in April
Mar 15, 2017
Lytix Biopharma featured in Mergermarket article
Mar 8, 2017
Lytix Biopharma presented at the 10th Annual European Life Sciences CEO Forum & Exhibition
Feb 3, 2017
Lytix Biopharma supports research at Weill Cornell Medicine, New York
Jan 30, 2017
Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway
Jan 13, 2017
Lytix Biopharma announces the appointment of Torbjørn Furuseth as CFO
Jan 6, 2017
Lytix Biopharma present at J.P. Morgan 35th Annual Healthcare Conference 2017, in San Francisco
Dec 22, 2016
Lytix enrols first patient in LTX-315/anti-PD1 combination study
Nov 29, 2016
Ongoing financing round
Nov 11, 2016
Håkan Wickholm presents Lytix Biopharma at Redeye Life Science Seminar 2016
Oct 19, 2016
Newsletter October 2016
Sep 21, 2016
Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors
Sep 21, 2016
Håkan Wickholm presents Lytix Biopharma at Sachs Annual Biotech in Europe Forum
Sep 20, 2016
LTX-315 presented at Basel Life Science week
Sep 15, 2016
Lytix Biopharma present at Nordic Life Science Days in Stockholm Sept 2016
Sep 1, 2016
Dr. Pittet at Massachusetts General Hospital and Harvard performs studies with LTX-315
Jun 14, 2016
LTX-315 in two oral presentations at WPC in Boston 14-16 June 2016
Jun 3, 2016
Lytix Biopharma attends BIO International Convention 2016
May 11, 2016
At CIMT 2016 Lytix presented LTX-315's ability to make tumors more T-cell inflamed
Apr 27, 2016
Newsletter April 2016
Apr 27, 2016
New LTX-315 article published in Cell Death and Differentiation
Apr 27, 2016
Lytix Biopharma will do a presentation at BioEquity Europe in Copenhagen in May
Apr 25, 2016
Immunotherapy works on a growing number of cancer types
Apr 15, 2016
Lytix Biopharma presented 4 posters at AACR in New Oreleans April 2016
Mar 30, 2016
The story behind the discovery of LTX-315 published in Journal of Medicinal Chemistry
Mar 21, 2016
A positive editorial discussion on LTX-315`s mode of action in the journal Cell Cycle
Mar 15, 2016
New LTX-315 paper in Cell Differentiation and Cell Cycle
Mar 2, 2016
Death of Prof. Holbrook Kohrt, SAB member
Mar 1, 2016
Håkan Wickholm new CEO, acting, in Lytix Biopharma
Feb 28, 2016
Lytix Biopharma is among promising cancer biotech companies featured in Norwegian article
Feb 22, 2016
Bent Høie, Minister of Health, killed cancer cells with LTX-315
Feb 11, 2016
Lytix Biopharma featured in article about collaboration in OCC Incubator
Jan 21, 2016
In a difficult marked, Lytix had a successful share issue - read article in DN
Jan 12, 2016
See the new video presentation of LTX-315 - its development and MoA
Dec 22, 2015
Lytix Biopharma granted patent in the US
Dec 15, 2015
Lytix Biopharma raises approximately 80 million NOK
Nov 23, 2015
Issuing of new shares in Lytix Biopharma, the subscription deadline is December 10, 2015
Nov 16, 2015
LTX-315 development history presented at European peptide conference
Nov 11, 2015
Lytix Biopharma in one of The 10 Hottest Bioincubators in Europe
Nov 9, 2015
Lytix Biopharma presented LTX-315 at melanoma conference in Rome
Nov 2, 2015
Newsletter November 2015
Nov 2, 2015
Lytix Biopharma announces prominent Scientific and Clinical Advisory Board
Oct 31, 2015
Lytix Biopharma shelves clinical trial with LTX-109 in diabetic foot ulcers
Oct 16, 2015
A new paper with LTX-315 published in Oncotarget
Sep 28, 2015
TV lecture on antibacterial compounds by one of Lytix Biopharma's founders
Sep 26, 2015
Lytix Biopharma presented initial results from LTX-315 Phase I study at ECC2015
Sep 21, 2015
LTX-315 paper published in Oncotarget
Sep 9, 2015
Lytix Biopharma in panel discussion at Nordic Life Science Days in Stockholm Sept 9th 2015
Sep 9, 2015
Political seminar on knowledge-based reorganization to new growth and value creation
Aug 25, 2015
Lytix Biopharma’s preclinical activity moves into OCCI
Jun 22, 2015
Lytix Biopharma presents poster at Melanoma Conference in Reykjavik
Jun 15, 2015
Lytix Biopharma attends BIO International Convention 2015
Jun 12, 2015
Lytix Biopharma announces Gert W. Munthe as new Chairman of the Board
Jun 10, 2015
Newsletter June 2015
Jun 1, 2015
Lytix Biopharma represented and interviewed at ASCO in Chigaco
May 13, 2015
Lytix Biopharma invited to speak at Scandinavian Sarcoma group meeting in Stockholm
Apr 24, 2015
Lytix Biopharma announces a Proof of Concept milestone for LTX-315
Apr 23, 2015
Lytix Biopharma presented at Anglonordic Life Science Conference XII in London
Apr 21, 2015
Lytix Biopharma at AACR with poster
Mar 11, 2015
'Research and innovation in interest of the patient'
Mar 9, 2015
Lytix Biopharma attends BIO-Europe Spring 2015 in Paris
Mar 3, 2015
New collaboration period with Institut Gustave Roussy
Mar 3, 2015
Newsletter March 2015
Mar 2, 2015
Lytix Biopharma presented at Arctic Securities' Biotech Seminar
Feb 18, 2015
Lytix Biopharma presented at Bioprosp_15 in Tromsø February 18th
Feb 5, 2015
Lytix Biopharma featured in ‘Norsk Industris Konjunkturrapport 2015’
Dec 22, 2014
NOK 50 million raised in Lytix Biopharma
Dec 2, 2014
Listing of new shares in Lytix Biopharma, the subscription deadline is December 17, 2014
Nov 21, 2014
Lytix Biopharma appoints Andrew Saunders, M.D., FFPM as Chief Medical Officer
Nov 10, 2014
Lytix Biopharma attended SITC in Washington Nov 6-9, 2014
Oct 31, 2014
‘New star’ – Lytix Biopharma recognized in Aftenposten
Oct 29, 2014
New article about LTX-109 published in ‘Antimicrobial Agents and Chemotherapy’
Oct 16, 2014
Extension of the order period for placement in Lytix Amicoat AS
Oct 9, 2014
In his speach Oct 8th Minister Røe Isaksen put Lytix Biopharma forward as a good example
Sep 24, 2014
Lytix Biopharma got honored guests - NoMA Tuesday and two ministers Wednesday
Sep 20, 2014
CSO Øystein Rekdal invited as guest speaker at Karolinska
Sep 19, 2014
Lytix Biopharma attends ESMO in Madrid, Spain, Sept. 26-30, 2014
Sep 10, 2014
Newsletter September 2014
Sep 9, 2014
Lytix Biopharma awarded this year’s Nordic Stars Awards
Sep 8, 2014
Impetigo data presented at ICAAC, Washington D.C., sep 6th
Sep 5, 2014
LTX-315`s ability to cure B61 melanomas is published in two international journals
Sep 3, 2014
Lytix Biopharma focuses on immuno-oncology future
Aug 18, 2014
Lytix Biopharma attends Nordic Life Science Days in Stockholm September 7-9, 2014
Jul 7, 2014
Gert Munthe and Kari Dyvik joins the Board of Directors in Lytix Biopharma
Jun 23, 2014
Lytix Biopharma attends BIO International Convention 2014
Jun 10, 2014
Lytix Biopharma starts subsidiary within antimicrobial coating - Lytix Amicoat
Jun 6, 2014
Dr. Line presents LTX-315 data at International Liver Transplantation Society congress in London
Jun 2, 2014
Lytix Biopharma featured in media after presentation at ASCO
Jun 1, 2014
June 1st Lytix Bioharma presented data at ASCO from the first LTX-315 clinical trial
May 28, 2014
Lytix Biopharma extends the research collaboration with Institute Gustave Roussy
May 22, 2014
Lytix Biopharma features in 'Health Industry Conference' appendix
May 20, 2014
Newsletter May 2014
May 6, 2014
Lytix Biopharma enters into partnership dialogue about further development of LTX-109
Apr 30, 2014
Lytix Biopharma is attending Association for Cancer Immunotherapy (CIMT) meeting
Apr 25, 2014
Lytix Biopharma featured in Finansavisen regarding Pharmasum Therapeutics
Apr 16, 2014
'Tromsø company attracts attention at cancer congress' - article in iTromsø
Apr 10, 2014
Lytix Biopharma starts a new company within treatment of dementia, Pharmasum Therapeutics
Apr 7, 2014
Lytix Biopharma at AACR with 3 posters
Mar 31, 2014
Lytix Biopharma published new promising results with LTX-315
Feb 28, 2014
Extraordinary general assembly and shareholder meetings in Lytix Biopharma in March
Feb 5, 2014
Lytix Biopharma presented in economic report from the Norwegian Industry
Feb 1, 2014
Newsletter February 2014
Jan 29, 2014
Lytix Biopharma has been granted BIA funding for the cancer project (LTX-315)
Dec 5, 2013
'Successful share issue' featured in media
Dec 4, 2013
NOK 50 million subscribed in Lytix Biopharma
Nov 27, 2013
'First patient in new cancer study' featured in media
Nov 26, 2013
Lytix Biopharma included first patient in a new cancer study
Nov 25, 2013
John Sigurd Svendsen from Lytix Biopharma featured in Altaposten
Nov 22, 2013
Øystein Rekdal from Lytix Biopharma presents at 'Gazelle conference' in Tromsø Monday
Nov 20, 2013
Lytix Biopharma's drug candidate LTX-315 presented at AASLD in Washington
Nov 19, 2013
Lytix Biopharma’s antimicrobial drug candidate LTX-109 is one of ‘Top Projects To Watch’
Nov 15, 2013
Lytix Biopharma featured in Harstad Tidende
Nov 13, 2013
Norwegian cancer medicine presented at the world's largest liver congress
Nov 8, 2013
Lytix Biopharma receives Oslo Cancer Cluster immuno-oncology grant.
Oct 29, 2013
Invitation to shareholder meetings. News in Norwegian.
Oct 18, 2013
Listing of new shares in Lytix Biopharma. Minimum investment NOK 820 000.
Oct 17, 2013
Lytix Biopharma featured several times in Nordic press
Oct 17, 2013
Lytix Biopharma featured in iTromsø
Oct 16, 2013
Unni Hjelmaas interviewed in Dagens Næringsliv, 'På nattbordet'
Oct 15, 2013
LTX-315 is approved for a new exploratory phase I study in Europe
Oct 15, 2013
Lytix Biopharma 'blast' cancer cells in minutes - article in VG
Oct 14, 2013
Lytix Biopharma featured in Norwegian press, Dagens Næringsliv
Oct 1, 2013
Newsletter October 2013
Sep 27, 2013
Lytix Biopharma attended the 21st ECDO conference in Paris with poster
Sep 16, 2013
Lytix Biopharma attended ICAAC 2013, in Denver Colorado
Sep 2, 2013
Disputas - Sivilingeniør Ketil André Camilio
Aug 20, 2013
Lytix Biopharma attended the 53rd ICAAC annual meeting, 10-13 September in Denver, Colorado
Aug 6, 2013
Lytix Biopharma in Aftenposten
Aug 2, 2013
Lytix Biopharma featured in Norwegian financial press, Finansavisen
Jul 15, 2013
'Tromsø company with startling cancer findings', article in Nordlys
Jul 15, 2013
TV2 news coverage about Lytix Biopharma
Jun 17, 2013
LTX-315 kills cancer cells in minutes, article in Dagens Næringsliv
Jun 1, 2013
Newsletter June 2013
May 30, 2013
Lytix Biopharma attended ASCO (American Society of Clinical Oncology) annual meeting 2013
May 6, 2013
Lytix Biopharma attended CIMT (Cancer Immunotherapy) annual meeting 2013
Apr 12, 2013
Shareholder meeting in Harstad April 18th 2013
Apr 9, 2013
Lytix Biopharma attends BIO International Convention 2013
Apr 8, 2013
Lytix Biopharma attended the American Association for Cancer Research (AACR) annual meeting
Apr 3, 2013
Lytix Biopharma'’s infection drug candidate has the potential to treat and prevent skin infections
Feb 22, 2013
Lytix Biopharma enrolls first patient in LTX-109 Phase II PoC infection study
Feb 22, 2013
220213 Lytix Biopharma enrolls first patient in LTX-109 Phase II PoC infection study.htm
Nov 22, 2012
Shareholder meetings now finalized
Nov 7, 2012
Lytix Biopharma in Aftenposten
Nov 2, 2012
LTX-109 featured in newspaper article on antibiotic resistance in A-magasinet
Oct 30, 2012
301012 Lytix Biopharma and ABG Sundal COllier signs collaboration agreement
Oct 30, 2012
Lytix Biopharma and ABG Sundal Collier signs collaboration agreement
Oct 29, 2012
Invitation to shareholder meeting. News in Norwegian
Oct 23, 2012
Strategy meeting in Lytix Biopharma
Oct 15, 2012
Lytix Biopharma in one of the leading business newspapers in Norway
Aug 30, 2012
Government grant and share emission
Jul 5, 2012
Future by Semcon presenting Lytix Biopharma and Lytixar in the article "Antibiotics of the future".
May 31, 2012
LTX-315 presented at the 2012 GAP Conference in Oslo in May
May 15, 2012
Procedures for shareholder information
May 7, 2012
Lytix Biopharma innkaller til ordinær generalforsamling
Apr 17, 2012
Aksjonærbrev
Feb 28, 2012
Unni
Feb 28, 2012
Unni Hjelmaas has been appointed new CEO of Lytix Biopharma AS
Oct 11, 2011
ICAAC 2011
May 26, 2011
Successful Proof of Concept for topical antimicrobial drug Lytixar™ (LTX-109)
Dec 23, 2010
Lytix Biopharma closes successful shares emission | Lytix Biopharma gjennomfører vellykket emisjon
Dec 6, 2010
Lytix Biopharma and KAEL–GemVax announce first patient treated in clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy
Nov 30, 2010
Lytix Biopharma emisjon- Tid og sted for investorpresentasjoner
Sep 1, 2010
Lytix Biopharma AS announces approval by Hungarian authorities and ethics committee to start Phase IIa clinical trial with Lytixar™ (LTX-109) in Gram positive skin infections
Jun 9, 2010
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy
May 20, 2010
Lytix Biopharma AS announces regulatory approval by Swedish authorities to commence Phase I/IIa clinical trial with Lytixar™ (LTX-109) in MRSA
May 20, 2010
Lytix Biopharma AS update on phase I progress with Oncopore™ for solid tumours
May 4, 2010
Lytix Biopharma AS to hold General Assembly of Shareholders on 4th June 2010
Dec 14, 2009
Lytix Biopharma AS announces regulatory approval by Norwegian and Swedish authorities to commence Phase I clinical trial of OncoporeTM (LTX-315) in cancer
Sep 23, 2009
Lytix Biopharma presented new data on antimicrobial drug LytixarTM (LTX-109) at ICAAC
Aug 19, 2009
Lytix Biopharma announces start of dosing in Phase I trial
Jun 18, 2009
Lytix Biopharma and KAEL–GemVax announce joint clinical trial to combine LTX-315 and GV1001 cancer immunotherapy
Jun 2, 2009
Additional funding through shares emission and warrant scheme
Mar 24, 2009
Additional funding through shares emission and warrant scheme
Feb 26, 2009
Lytix Biopharma to expand team of drug development professionals
Jan 21, 2009
Lytix Biopharma closes successful funding round